Pfizer Inc (PFE) 30.19 $PFE
3 Dividend Value Stocks to Boost Your Income
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jul 26, 12:05PM CDT
Dividend stocks are more popular than ever, with investors looking for more income from their investments. But with many dividend stocks fetching high prices, how can you find good values in the dividend arena? In the following video, Dan...
Final Glance: Pharmaceuticals companies
AP - Fri Jul 25, 5:12PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were down at the close of trading:
Why Obama Has Attacked Cross-Border Mergers at This Particular Time
at The Street - Fri Jul 25, 4:39PM CDT
Obama is speaking out against corporate deserters, accusing companies of giving up their citizenship. His focus appears to be more on the election in the fall than on the economy.
Midday Glance: Pharmaceuticals companies
AP - Fri Jul 25, 12:42PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Pfizer (PFE) Breaks Through Support at $30.25
Comtex SmarTrend(R) - Fri Jul 25, 9:29AM CDT
Shares of Pfizer (NYSE
FE) opened today below their pivot of $30.41 and have already reached the first level of support at $30.25. Investors may be interested in a cross of the next downside pivot targets of $30.16 and $29.91.
Early Glance: Pharmaceuticals companies
AP - Fri Jul 25, 9:21AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 10 a.m.:
Premier Biomedical Gears Up for Two Important Clinical Trials
ACCESSWIRE - Fri Jul 25, 7:04AM CDT
Whitefish, MT / July 25, 2014 / Premier Biomedical Inc. (OTC: BIEI), a biopharmaceutical company focused on developing and commercializing innovative therapies targeting cancer, traumatic brain injury, Alzheimer's disease, MS and other serious conditions, recently announced that the William Beaumont Army Medical Center ("WBAMC"
has begun drafting a protocol that it plans to submit to their Institutional Review Board overseeing its double-blind clinical trial of Feldetrex(tm) in mid-August.
Is the Q2 Earnings Improvement Sustainable? - Earnings Preview
Sheraz Mian - Zacks Investment Research - Fri Jul 25, 3:08AM CDT
Is the Q2 Earnings Improvement Sustainable? - Earnings Preview
Most active New York Stock Exchange-traded stocks
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Shire, ArmaGen Ink Licensing Agreeement for AGT-182 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 5:00PM CDT
Shire (SHPG) recently entered into a worldwide licensing and collaboration agreement with U.S. based privately-held biotechnology company, ArmaGen.
Obama wants limits on US company mergers abroad
AP - Thu Jul 24, 4:32PM CDT
LOS ANGELES (AP) — Staking out a populist stand ahead of the midterm elections, President Barack Obama on Thursday demanded "economic patriotism" from U.S. corporations that use legal means to avoid U.S. taxes through overseas mergers.
Pfizer's Incoming Patent Cliff
Dan Carroll, The Motley Fool - Motley Fool - Thu Jul 24, 4:00PM CDT
Pfizer investors have had enough of the patent cliff already. The big pharma giant's loss of patent exclusivity on the world's former top-selling drug, cholesterol fighter Lipitor, has cost its drug revenues dearly. Pfizer's sales have fallen...
Bristol-Myers (BMY) Beats on Q2 Earnings, Maintains Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 4:00PM CDT
Bristol-Myers's (BMY) second quarter 2014 earnings of 46 cents per share beat the Zacks Consensus Estimate by 2 cents.
AmerisourceBergen Beats on Q3 Earnings & Revenues, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 3:45PM CDT
AmerisourceBergen Corp. (ABC) posted earnings of $1.01 per share in the third quarter of fiscal 2014 (ended Jun 30, 2014), which beat the Zacks Consensus Estimate of 92 cents.
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 12:48PM CDT
The rise in healthcare spending, if true, will increase business for hospitals, diagnostic centers and healthcare related industry. Eventually, the healthcare industry should benefit and help healthcare funds be better investment potential.
Bristol 2Q net drops on lower drug sales, charges
AP - Thu Jul 24, 9:53AM CDT
NEW YORK (AP) — Bristol-Myers Squibb Co.'s exit from the diabetes business, plus higher taxes and research spending, combined to slash the drugmaker's second-quarter profit by 38 percent, but the company handily beat Wall Street's muted profit expectations.
Michigan governor's campaign met with ambivalence
AP - Thu Jul 24, 9:14AM CDT
LANSING, Mich. (AP) — Michigan Gov. Rick Snyder has accomplished much of what he set out to do when he was elected four years ago. He's logged improvements in the state's economic health, presided over the creation of 250,000 private-sector jobs and confronted many of Detroit's worsening financial problems.
3 Dividend Value Stocks to Boost Your Income
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jul 26, 12:05PM CDT
Dividend stocks are more popular than ever, with investors looking for more income from their investments. But with many dividend stocks fetching high prices, how can you find good values in the dividend arena? In the following video, Dan...
Final Glance: Pharmaceuticals companies
AP - Fri Jul 25, 5:12PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were down at the close of trading:
Why Obama Has Attacked Cross-Border Mergers at This Particular Time
at The Street - Fri Jul 25, 4:39PM CDT
Obama is speaking out against corporate deserters, accusing companies of giving up their citizenship. His focus appears to be more on the election in the fall than on the economy.
Midday Glance: Pharmaceuticals companies
AP - Fri Jul 25, 12:42PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Pfizer (PFE) Breaks Through Support at $30.25
Comtex SmarTrend(R) - Fri Jul 25, 9:29AM CDT
Shares of Pfizer (NYSE
FE) opened today below their pivot of $30.41 and have already reached the first level of support at $30.25. Investors may be interested in a cross of the next downside pivot targets of $30.16 and $29.91. Early Glance: Pharmaceuticals companies
AP - Fri Jul 25, 9:21AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 10 a.m.:
Premier Biomedical Gears Up for Two Important Clinical Trials
ACCESSWIRE - Fri Jul 25, 7:04AM CDT
Whitefish, MT / July 25, 2014 / Premier Biomedical Inc. (OTC: BIEI), a biopharmaceutical company focused on developing and commercializing innovative therapies targeting cancer, traumatic brain injury, Alzheimer's disease, MS and other serious conditions, recently announced that the William Beaumont Army Medical Center ("WBAMC"
has begun drafting a protocol that it plans to submit to their Institutional Review Board overseeing its double-blind clinical trial of Feldetrex(tm) in mid-August. Is the Q2 Earnings Improvement Sustainable? - Earnings Preview
Sheraz Mian - Zacks Investment Research - Fri Jul 25, 3:08AM CDT
Is the Q2 Earnings Improvement Sustainable? - Earnings Preview
Most active New York Stock Exchange-traded stocks
AP - Thu Jul 24, 5:23PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Shire, ArmaGen Ink Licensing Agreeement for AGT-182 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 5:00PM CDT
Shire (SHPG) recently entered into a worldwide licensing and collaboration agreement with U.S. based privately-held biotechnology company, ArmaGen.
Obama wants limits on US company mergers abroad
AP - Thu Jul 24, 4:32PM CDT
LOS ANGELES (AP) — Staking out a populist stand ahead of the midterm elections, President Barack Obama on Thursday demanded "economic patriotism" from U.S. corporations that use legal means to avoid U.S. taxes through overseas mergers.
Pfizer's Incoming Patent Cliff
Dan Carroll, The Motley Fool - Motley Fool - Thu Jul 24, 4:00PM CDT
Pfizer investors have had enough of the patent cliff already. The big pharma giant's loss of patent exclusivity on the world's former top-selling drug, cholesterol fighter Lipitor, has cost its drug revenues dearly. Pfizer's sales have fallen...
Bristol-Myers (BMY) Beats on Q2 Earnings, Maintains Outlook - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 4:00PM CDT
Bristol-Myers's (BMY) second quarter 2014 earnings of 46 cents per share beat the Zacks Consensus Estimate by 2 cents.
AmerisourceBergen Beats on Q3 Earnings & Revenues, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 3:45PM CDT
AmerisourceBergen Corp. (ABC) posted earnings of $1.01 per share in the third quarter of fiscal 2014 (ended Jun 30, 2014), which beat the Zacks Consensus Estimate of 92 cents.
Healthcare Spending to Trend Up in 2015: 3 Healthcare Fund Picks - Best of Funds
Zacks Equity Research - Zacks Investment Research - Thu Jul 24, 12:48PM CDT
The rise in healthcare spending, if true, will increase business for hospitals, diagnostic centers and healthcare related industry. Eventually, the healthcare industry should benefit and help healthcare funds be better investment potential.
Bristol 2Q net drops on lower drug sales, charges
AP - Thu Jul 24, 9:53AM CDT
NEW YORK (AP) — Bristol-Myers Squibb Co.'s exit from the diabetes business, plus higher taxes and research spending, combined to slash the drugmaker's second-quarter profit by 38 percent, but the company handily beat Wall Street's muted profit expectations.
Michigan governor's campaign met with ambivalence
AP - Thu Jul 24, 9:14AM CDT
LANSING, Mich. (AP) — Michigan Gov. Rick Snyder has accomplished much of what he set out to do when he was elected four years ago. He's logged improvements in the state's economic health, presided over the creation of 250,000 private-sector jobs and confronted many of Detroit's worsening financial problems.
